Citations

Citations to this article as recorded by  

• Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
  Xiao-Dong Zhou, Qiong-Yue Fan, Christopher D Byrne, Giovanni Targher, Mark D Muthiah, Daniel Q Huang, Qin-Fen Chen, Mazen Noureddin, Wenhao Li, Vlad Ratziu, Rohit Loomba, Sven M Francque, Arun J Sanyal, Ming-Hua Zheng
  Gut.2025; : gutjnl-2025-337431.     CrossRef

Citations

Citations to this article as recorded by  

• GH Replacement Therapy Is Associated with Ameliorations in Body Composition and Fatty Liver Index in Patients with Adult-Onset Isolated GH Deficiency
  Elena Gangitano, Rebecca Rossetti, Giusy Simeone, Mariaignazia Curreli, Orietta Gandini, Stefania Mariani, Carla Lubrano
  Livers.2025; 5(4): 56.     CrossRef
• Prognostic value of coronary artery calcium score for the prediction of atherosclerotic cardiovascular disease in participants with suspected nonalcoholic hepatic steatosis: Results from the multi-ethnic study of atherosclerosis
  Keishi Ichikawa, Spencer Hansen, Venkat S. Manubolu, Leili Pourafkari, Hooman Fazlalizadeh, Jairo Aldana-Bitar, Lisa B. VanWagner, Srikanth Krishnan, Matthew J. Budoff
  American Heart Journal.2023; 265: 104.     CrossRef
• The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
  Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
  Diagnostics.2023; 13(21): 3316.     CrossRef

Citations

Citations to this article as recorded by  

• Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019
  Jacob Romano, Jessica Burnside, Giada Sebastiani, Alnoor Ramji, Keyur Patel, Mark Swain, Sahar Saeed
  Annals of Hepatology.2025; 30(1): 101757.     CrossRef
• Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease—the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression
  Sinéad M Mullin, Aidan J Kelly, Méabh B Ní Chathail, Suzanne Norris, Christopher E Shannon, Helen M Roche
  Advances in Nutrition.2025; 16(3): 100375.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk
  Vlad Alexandru Ionescu, Gina Gheorghe, Nicolae Bacalbasa, Camelia Cristina Diaconu
  Biomolecules.2025; 15(2): 163.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease correlates with higher lower graft survival in liver transplant recipients with hepatocellular carcinoma
  Marwan Alsaqa, Leandro Sierra, Ana Marenco-Flores, Ximena Parraga, Romelia Barba, Daniela Goyes, N. Begum Ozturk, Michael P. Curry, Alan Bonder, Behnam Saberi
  European Journal of Gastroenterology & Hepatology.2025; 37(4): 497.     CrossRef
• Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study
  Javier Díaz Carnicero, Inma Saurí-Ferrer, Josep Redon, Jorge Navarro, Gonzalo Fernández, Carlos Hurtado, Karine Ferreira, Carolina Alvarez-Ortega, Antón Gómez, Carlos J. Martos-Rodríguez, David Martí-Aguado, Desamparados Escudero, Marta Cedenilla
  Journal of Clinical Medicine.2025; 14(7): 2441.     CrossRef
• MASLD or MAFLD: fatty liver by any name will pose the same challenge
  Anil Chandra Anand, Dibyalochan Praharaj
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Cardiac Remodeling and Arrhythmic Burden in Pre-Transplant Cirrhotic Patients: Pathophysiological Mechanisms and Management Strategies
  Charilila-Loukia Ververeli, Yannis Dimitroglou, Stergios Soulaidopoulos, Evangelos Cholongitas, Constantina Aggeli, Konstantinos Tsioufis, Dimitris Tousoulis
  Biomedicines.2025; 13(4): 812.     CrossRef
• Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
  Soon Kyu Lee, Jong Young Choi
  Clinical and Molecular Hepatology.2025; 31(2): e212.     CrossRef
• Risk Factors Related to the Development of Nonalcoholic Fatty Liver: A Systematic Review
  Omaira Valencia, Carolina López, Esteban Vanegas-Duarte, Carolina Fillizola, Diana Fernanda Bejarano Ramírez, Nicolás Andrés Cortés Mejía, Alonso Vera Torres, Kevork M. Peltekian
  Canadian Journal of Gastroenterology and Hepatology.2025;[Epub]     CrossRef
• Safety, efficacy, and outcomes of invasive coronary angiography in liver transplant candidates
  Carme Ginard, Giulia Pagano, Salvatore Brugaletta, Annabel Blasi, Marta Sánchez-Ric, Ander Regueiro, Roger Pujol, Sergio Rodriguez-Tajes, Pablo Ruiz, Jordi Colmenero, Gonzalo Crespo
  JHEP Reports.2025; 7(7): 101428.     CrossRef
• The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort
  Qi Feng, Chioma N Izzi-Engbeaya, Andrea D Branch, Benjamin H Mullish, Pinelopi Manousou, Mark Woodward
  The Journal of Clinical Endocrinology & Metabolism.2025; 111(1): e58.     CrossRef
• MAFLD as a Cardiovascular Risk Factor: An Extended Retrospective Study with a Control Group
  Małgorzata Szymala-Pędzik, Marcin Piersiak, Maciej Pachana, Karolina Lindner-Pawłowicz, Wioletta Szczepaniak, Małgorzata Sobieszczańska
  Journal of Clinical Medicine.2025; 14(12): 4181.     CrossRef
• Metabolic-associated fatty liver disease: Noninvasive diagnosis and assessment of liver fibrosis
  O. O. Karshina, I. S. Sabirov
  Meditsinskiy sovet = Medical Council.2025; (8): 72.     CrossRef
• Are we standing on the shifting sands of post-transplant metabolic-associated steatotic liver disease?
  Renata Zatta, Luana S da Silva, Guilherme Felga, Carolina FMG Pimentel
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States
  Marika Hancock, Cayden Beyer, Michael Fuchs, Mukesh Harisinghani, Prasun Jalal, Michael Ndaa, Niharika Samala, Jose D. Vargas, Arjun Jayaswal
  Journal of Medical Economics.2025; 28(1): 1370.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
  Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, Adnan Alzanbagi, Ahmed Aljedai, Ali Alshehri, Assim Alfadda, Hamdan Alghamdi, Majid Almadi, Mohammad Aleissa, Mona Ismail, Saud Alsifri, Turki Alzahrani, Saleh Alqahtani, Waleed Al Hamoudi
  Saudi Journal of Gastroenterology.2025;[Epub]     CrossRef
• Integrated Genomic Analysis Reveals the Synergistic Role of PNPLA3 and ABCC8 Variants in Diabetic MASLD in Pakistan
  Asma Shabbir, Ambrina Khatoon, Zaigham Abbas, Sucheta Srivastava, Talat Mirza
  Medical Sciences.2025; 13(3): 178.     CrossRef
• Sex-Stratified Prediction Models for 5-Year Nonalcoholic Fatty Liver Disease Risk in Thyroid Cancer Patients: A Nationwide Cohort Study
  Young Bin Cho, Kyoung Sik Park
  Biomedicines.2025; 13(9): 2250.     CrossRef
• Genome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention
  Leonardo Leal-Mercado, Arturo Panduro, Alexis José-Abrego, Sonia Roman
  International Journal of Molecular Sciences.2025; 26(18): 8977.     CrossRef
• Validation of MELD 3.0 and ReMELD-Na scoring systems: a German clinical cohort study
  Aghnia J. Putri, Decan Jiang, Zoltan Czigany, Arianeb Mehrabi, Markus Wolfgang Buechler, Uta Merle, Christoph Michalski, Peri Husen
  Langenbeck's Archives of Surgery.2025;[Epub]     CrossRef
• How best to combine liver transplantation and bariatric surgery?—Results from a global, web‐based survey
  Jeannette Widmer, Janina Eden, Fariba Abbassi, Roberta Angelico, Fabian Rössler, Beat Müllhaupt, Philipp Dutkowski, Marco Bueter, Andrea Schlegel
  Liver International.2024; 44(2): 566.     CrossRef
• Exploring the effects of epigallocatechin gallate on lipid metabolism in the rat steatotic liver during normothermic machine perfusion: Insights from lipidomics and RNA sequencing
  Shuxuan Li, Yao Zhi, Wentao Mu, Mingqian Li, Guoyue Lv
  European Journal of Pharmacology.2024; 964: 176300.     CrossRef
• Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
  Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo
  Biomedicines.2024; 12(2): 397.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
  Arghya Samanta, Moinak Sen Sarma
  World Journal of Hepatology.2024; 16(4): 511.     CrossRef
• Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
  David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse, Alexandra Kraut, Justine Barthelon, Nathalie Sturm, Hélène Borges, Salomé Biennier, Marie Courçon, Marc de Saint Loup, Victoria Mignot, Charlotte Costentin, Thomas Burger, Yohann Couté, Christophe Bru
  Biomarker Research.2024;[Epub]     CrossRef
• Cardiac abnormalities pre- and post-liver transplantation for metabolic dysfunction-associated steatohepatitis – Evidence and special considerations
  Steven M. Elzein, Elizabeth W. Brombosz, Sudha Kodali
  Journal of Liver Transplantation.2024; 15: 100228.     CrossRef
• Serum Creatinine as an Independent Predictor of Moderate to Severe Fibrosis in Chinese American Non-obese Metabolic Dysfunction-Associated Steatotic Liver Disease
  Michael Sun, Vincent J Yao, Aivi A Rahman, Kevin Liu, Saud Rehman, Amber Sun, Alan C Yao
  Cureus.2024;[Epub]     CrossRef
• Recent trends and new developments in liver transplantation
  Yasuhiko Sugawara, Taizo Hibi
  BioScience Trends.2024; 18(3): 206.     CrossRef
• Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice
  Guanliang Chen, Yanwen Yu, Yuqin Zhu, Mayumi Nagashimada, Yajiao Wang, Naoto Nagata, Liang Xu
  Endocrinology.2024;[Epub]     CrossRef
• Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
  Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan
  Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
• The interrelation of cardiometabolic risk factors and metabolic dysfunction-associated steatotic liver disease subtypes
  A. Yu. Ishchenko, M. Yu. Galushko, I. G. Bakulin
  Meditsinskiy sovet = Medical Council.2024; (15): 146.     CrossRef
• Cardio-metabolic disorders in a patient with non-alcoholic fatty liver disease and normal body weight
  Svetlana V. Turkina, Mikhail E. Statsenko, Irina A. Tyshchenko, Marina N. Titarenko, Marina A. Kosivtsova, Elena E. Gorbacheva
  Journal of Volgograd State Medical University.2024; 21(3): 109.     CrossRef
• Exploring the knowledge and attitudes towards metabolic dysfunction associated fatty liver disease (MAFLD): Validation and correlations of MAFLD-knowledge questionnaire and MAFLD-attitude questionnaire
  Samah Al Tawil, Mohamad Abdelkhalik, Adam El Fouani, Nour Allakiss, Lama Mattar, Wissam H. Faour, Rajaa Chatila
  Heliyon.2024; 10(22): e40217.     CrossRef
• Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study
  José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente
  Nutrients.2024; 16(22): 3857.     CrossRef
• Liver transplantation for alcohol-related liver disease in Korea: The need for patient management guidelines
  Soon Kyu Lee
  Annals of Liver Transplantation.2024; 4(2): 40.     CrossRef
• Post-transplant complications in alcohol- and metabolic-associated steatotic liver disease
  Shekhar Singh Jadaun, Sanjiv Saigal
  Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
• How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
  Byeong Geun Song, Dong Hyun Sinn
  Clinical and Molecular Hepatology.2023; 29(2): 411.     CrossRef
• Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
  Qingfu Dong, Haolin Bao, Jiangang Wang, Wujiang Shi, Xinlei Zou, Jialin Sheng, Jianjun Gao, Canghai Guan, Haoming Xia, Jinglin Li, Pengcheng Kang, Yi Xu, Yunfu Cui, Xiangyu Zhong
  Frontiers in Medicine.2023;[Epub]     CrossRef
• Diabetes and Metabolic Disorders: Their Impact on Cardiovascular Events in Liver Transplant Patients
  Simone Di Cola, Giulia Cusi, Lucia Lapenna, Jakub Gazda, Stefano Fonte, Marco Mattana, Gianluca Mennini, Patrizio Pasqualetti, Manuela Merli, Xingshun Qi
  Canadian Journal of Gastroenterology and Hepatology.2023; 2023: 1.     CrossRef
• Evaluation and Management of Nutritional Consequences of Chronic Liver Diseases
  Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, María José Domper-Arnal, Sandra García-Mateo, Alberto Lué
  Nutrients.2023; 15(15): 3487.     CrossRef
• New Developments and Challenges in Liver Transplantation
  Amjad Khalil, Alberto Quaglia, Pierre Gélat, Nader Saffari, Hassan Rashidi, Brian Davidson
  Journal of Clinical Medicine.2023; 12(17): 5586.     CrossRef
• Outcomes in elderly patients undergoing hepatic resection compared to liver transplant for hepatocellular carcinoma
  Sameer A. Khan, Fasih A. Ahmed, Muhammad S. Hafeez, Lawrence R. Feng, Abhinav Seth, Yong K. Kwon, Hassan Aziz
  Journal of Surgical Oncology.2023; 128(8): 1320.     CrossRef

Citations

Citations to this article as recorded by  

• Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
  European Journal of Gastroenterology & Hepatology.2026; 38(1): 63.     CrossRef
• Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort
  Qi Feng, Pinelopi Manousou, Chioma N. Izzi‐Engbeaya, Rohit Loomba, Mark Thursz, Mark Woodward
  Liver International.2026;[Epub]     CrossRef
• Secondary Growth Hormone Deficiency That Developed into Cirrhosis after Several Years of Interrupted Growth Hormone Replacement Therapy
  Ayana Sueki, Daisuke Kaya, Shinsaku Nagamatsu, Chisa Yamamoto, Kohei Ohta, Yuya Matsuo, Yuya Nishio, Yusuke Komeda, Shoma Kikukawa, Kyohei Matsuura, Hideki Matsuo, Masakazu Uejima, Kei Moriya
  Internal Medicine.2025; 64(3): 387.     CrossRef
• Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
  Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
  American Journal of Gastroenterology.2025; 120(2): 410.     CrossRef
• The Fibrosis-4 index predicts all-cause mortality in a cohort of patients at high cardiovascular risk partly through glomerular filtration rate reduction
  Antonio Mirijello, Gabriella Pacilli, Antonio Siena, Antonio Mangiacotti, Maria Maddalena D'Errico, Daria Dilalla, Olga Lamacchia, Andrea Fontana, Massimiliano Copetti, Pamela Piscitelli, Giovanni Targher, Salvatore A. De Cosmo
  Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(1): 103768.     CrossRef
• Secondhand Smoke Exposure and Metabolic Dysfunction-associated Steatotic Liver Disease in US Adolescents
  Donghee Kim, Brandon J. Perumpail, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
  Clinical Gastroenterology and Hepatology.2025; 23(4): 665.     CrossRef
• Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
  Yewan Park, Jooyi Jung, Gi‐Ae Kim
  Alimentary Pharmacology & Therapeutics.2025; 61(2): 400.     CrossRef
• Red cell distribution width/platelet ratio predicts decompensation of metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease
  Ming-Hua Zheng, Amedeo Lonardo
  World Journal of Gastroenterology.2025;[Epub]     CrossRef
• PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
  Baokai Sun, Likun Zhuang
  Clinical and Molecular Hepatology.2025; 31(1): e67.     CrossRef
• Role of noninvasive tests on the prediction of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data
  Nanicha Siriwong, Supachaya Sriphoosanaphan, Pakanat Decharatanachart, Tanat Yongpisarn, Stephen J. Kerr, Sombat Treeprasertsuk, Thodsawit Tiyarattanachai, Terapap Apiparakoon, Hannes Hagström, Camilla Akbari, Mattias Ekstedt, Terry Cheuk-Fung Yip, Grace
  European Journal of Gastroenterology & Hepatology.2025; 37(3): 358.     CrossRef
• Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
  Yu-Ming Cheng, Shao-Wen Wang, Ching Wang, Chia-Chi Wang
  Tzu Chi Medical Journal.2025; 37(2): 152.     CrossRef
• Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank
  Tae Seop Lim, Sujin Kwon, Sung A. Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
  Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
• Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
  Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso
  Exploration of Medicine.2025;[Epub]     CrossRef
• The relationship between serum uric acid level and non-alcoholic fatty liver disease in northern China: a retrospective cohort study
  Qian He, Xinyue Liu, Guoyong Ding, Yiying Wang, Xiaoting Luo, Wenyuan Cao, Weijia Xing
  BMC Public Health.2025;[Epub]     CrossRef
• Novel pyranopyridine derivatives and their radiolabeled nanoconjugates: An augmented approach for targeted cancer theranostics
  Hesham A. Shamsel-Din, Mohamed M. Swidan, Ahmed B. Ibrahim, Mohamed A. Motaleb, Tamer M. Sakr
  Journal of Drug Delivery Science and Technology.2025; 107: 106802.     CrossRef
• Metabolic dysfunction-associated steatotic liver disease in adults
  Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba
  Nature Reviews Disease Primers.2025;[Epub]     CrossRef
• Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017–2020
  Xin Liao, Song Yu, Lin Wang, Ruyue Zhang, Ke Yu
  Frontiers in Physiology.2025;[Epub]     CrossRef
• Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
• Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): e180.     CrossRef
• The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): e183.     CrossRef
• Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(2): 382.     CrossRef
• Associations between non-insulin-based insulin resistance surrogate markers and liver-related outcomes in metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study in South Korea
  Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek
  BMC Gastroenterology.2025;[Epub]     CrossRef
• Response to the Letter to the Editor: What Is the Optimal Anti‐Diabetic Regimen Among CHB and T2DM Patients?
  Beom Kyung Kim
  Liver International.2025;[Epub]     CrossRef
• The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography
  Xinrui Jin, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jimmy Che-To Lai
  Ultrasonography.2025; 44(3): 189.     CrossRef
• Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease
  Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi
  Journal of Advanced Research.2025;[Epub]     CrossRef
• Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease in Children with Down Syndrome at a Tertiary Care Center
  Maria D. Karaceper, Maria-Jose Villegas, Sanathan Sadh, Sierra Kawesa, Jamie Strain, Asha Nair, Alissa Dupuis, Mary Pothos, Ming-Hua Zheng, Mohit Kehar
  Journal of Clinical Medicine.2025; 14(9): 3239.     CrossRef
• The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco
  Journal of Clinical Medicine.2025; 14(11): 3821.     CrossRef
• Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade
  Hideyuki Tamai, Jumpei Okamura
  Hepatology Research.2025; 55(9): 1274.     CrossRef
• Association between impaired sensitivity to thyroid hormones and sedentary behavior: a cross-sectional study
  Hangzhou Yang, Jie Kang, Lingkang Dong, Zihan Lin, Qixian Lin, Bo Wu
  Frontiers in Medicine.2025;[Epub]     CrossRef
• ECM formation and degradation during fibrosis, repair, and regeneration
  Alejandro E. Mayorca-Guiliani, Diana Julie Leeming, Kim Henriksen, Joachim Høg Mortensen, Signe Holm Nielsen, Quentin M. Anstee, Arun J. Sanyal, Morten A. Karsdal, Detlef Schuppan
  npj Metabolic Health and Disease.2025;[Epub]     CrossRef
• Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
  Donghee Kim, Rohit Loomba, Aijaz Ahmed
  Clinical and Molecular Hepatology.2025; 31(3): e235.     CrossRef
• The Burden of Nonmalignant Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Western Pacific Region: A Systematic Analysis From 1990 to 2021
  Qichao Ge, Yuan Lin, Mingwang Wang, Jianwei Zhu, Qingqing Zhang, Junjun Wang, Yufei Yang, Hanjing Zhangdi, Yuecheng Guo, Shanjuan Wang, Lungen Lu
  Food Science & Nutrition.2025;[Epub]     CrossRef
• The association between serum pinenes and non-alcoholic fatty liver disease based on the NHANES 2013–2014
  Tuo Xiao, Xue Xing, Lulu Sun, Jin Shang
  Ecotoxicology and Environmental Safety.2025; 302: 118712.     CrossRef
• Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study
  Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Bartosz Dobies, Kolbrun Sveinsdottir, Ari Pall Isberg, Gudlaug E A Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, Sigurdur Sigurdsson, Saemundur Oddsson
  JMIR Cardio.2025; 9: e72074.     CrossRef
• Reliability of Ultrasonic Hepatorenal Indices in Assessing Hepatic Steatosis: A Systematic Review and Meta‐Analysis
  Jin‐Li Wang, Jian Dong, Si‐Rui Wang, Chun‐Li Cao, Jin Tong, WenXiao Li, Ting‐Ting Du, Ting‐Ting He, Xiao‐Wu Yuan, Jun Li, Hong Zhai
  Journal of Clinical Ultrasound.2025;[Epub]     CrossRef
• The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial
  Mohammad Mahmoudi Azar, Matin Shirazinia, Mohsen Nematy, Vafa Baradaran Rahimi, Motahare Bateni, Fateme Tafaghodi Piadeh Gheibi, Farnood Rajabzadeh, Ladan Goshayeshi, Sara Honari, Mehran Mottahedi, Vahid Reza Askari
  Inflammopharmacology.2025; 33(9): 5583.     CrossRef
• Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease
  Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
  Gut and Liver.2025; 19(5): 758.     CrossRef
• Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
  Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
  Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
• Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
• Placebo Rates in Metabolic Dysfunction–Associated Steatohepatitis Clinical Trials: A Systematic Review and Meta-Analysis
  Francisco Idalsoaga, Luis Antonio Díaz, Saleh Alghsoon, Bishoy Lawendy, Neha Sharma, Hailemichael Desalegn, Yuhong Yuan, My Ha, Jessica Le, John K. MacDonald, Marco Arrese, Rohit Loomba, Vipul Jairath, Mohammad Qasim Khan, Juan Pablo Arab
  Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
• Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
• Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends
  George S Zacharia, Muhammad H Ashraf, Franklin Sosa, Anu Jacob, Harish Patel
  World Journal of Gastrointestinal Pharmacology and Therapeutics.2025;[Epub]     CrossRef
• Sex-specific differences in the prognostic value of METS-IR for long-term outcomes in patients with MASLD and advanced liver fibrosis: a nationwide study
  Binbin Song, Yuan Zhou, Rui Su, Yan Wang, Song Chen, Wenjin Chen
  European Journal of Medical Research.2025;[Epub]     CrossRef
• Cost‐effectiveness study of FIB‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at‐risk population
  Huiyul Park, Eileen L. Yoon, Mimi Kim, Sun‐Hong Kwon, Donghee Kim, Ramsey Cheung, Hye‐Lin Kim, Dae Won Jun
  Liver International.2024; 44(4): 944.     CrossRef
• Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
  Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
  Gut and Liver.2024; 18(2): 283.     CrossRef
• Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
  Richie Manikat, Aijaz Ahmed, Donghee Kim
  Alimentary Pharmacology & Therapeutics.2024; 59(7): 893.     CrossRef
• Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
  Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Alimentary Pharmacology & Therapeutics.2024; 60(1): 33.     CrossRef
• Estimated pulse wave velocity in metabolic dysfunction‐associated steatotic liver disease and all‐cause/cause‐specific mortality
  Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Journal of Gastroenterology and Hepatology.2024; 39(9): 1950.     CrossRef
• Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge
  Mohamad Jamalinia, Amedeo Lonardo
  Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
• Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records
  Ignat Drozdov, Benjamin Szubert, Ian A. Rowe, Timothy J. Kendall, Jonathan A. Fallowfield
  Annals of Hepatology.2024; 29(5): 101528.     CrossRef
• The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
  David R. Riley, Theresa Hydes, Gema Hernadez, Sizheng S. Zhao, Uazman Alam, Daniel J. Cuthbertson
  Liver International.2024; 44(10): 2538.     CrossRef
• The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease
  Do Seon Song
  Gut and Liver.2024; 18(4): 562.     CrossRef
• Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups
  Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Kyu Na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
  Cardiovascular Diabetology.2024;[Epub]     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic
  Akira Sato, Yumiko Oomori, Rika Nakano, Tomokazu Matsuura
  Medicina.2024; 60(8): 1330.     CrossRef
• Contemporary awareness of nonalcoholic fatty liver disease and viral hepatitis based on the stage
  Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  The American Journal of the Medical Sciences.2024; 368(6): 685.     CrossRef
• High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease
  Jingjing Hu, Yuteng Du, Yidan Zhou, Huiying Wang
  Scientific Reports.2024;[Epub]     CrossRef
• Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups
  Jaejun Lee, Jae Hyeop Jung, Sung Jun Choi, Beomman Ha, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Jeong-A Yu
  Gut and Liver.2024; 18(5): 888.     CrossRef
• Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
  Ewelina Książek, Zuzanna Goluch, Marta Bochniak
  Nutrients.2024; 16(17): 2940.     CrossRef
• Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
  Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan
  Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
• Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
  Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
  Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599.     CrossRef
• Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
  Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
  Cancers.2024; 16(18): 3161.     CrossRef
• Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun
  Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li
  Clinical and Molecular Hepatology.2024; 30(4): 974.     CrossRef
• Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
  Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
  Clinical and Molecular Hepatology.2024; 30(4): 982.     CrossRef
• Unraveling the Association of Liver Steatosis and Fibrosis with Vitamin B12: A Cross-Sectional Study
  Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, Ana Royo-Esteban, Maria Pilar García-Sobreviela, Pilar Calmarza, Ana B. Martinez-Martinez, Jesús Osada, Jose M. Arbones-Mainar
  Metabolites.2024; 14(11): 618.     CrossRef
• Association between Body Fat Distribution and Nonalcoholic Fatty Liver Disease/Fibrosis Based on Race/Ethnicity
  Donghee Kim, George Cholankeril, Aijaz Ahmed
  Journal of Obesity & Metabolic Syndrome.2024; 33(4): 326.     CrossRef
• Nonlinear correlation between fatty liver index and carotid intima media thickness among individuals undergoing health examination
  Yuanchen Zhou, Shaojie Duan, Rongrui Wang, Jialiang Chen, Shukun Yao
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• The growing burden of non-alcoholic fatty liver disease on mortality
  Ju-Yeon Cho, Won Sohn
  Clinical and Molecular Hepatology.2023; 29(2): 374.     CrossRef
• Discovery of new pyridine heterocyclic hybrids; design, synthesis, dynamic simulations, and in vitro and in vivo breast cancer biological assays
  Menna M. Abdelshaheed, Hussein I. El Subbagh, Mohamed A. Tantawy, Reem T. Attia, Khairia M. Youssef, Iten M. Fawzy
  RSC Advances.2023; 13(23): 15689.     CrossRef
• Synergistic Preventive Effect of Aerobic and Resistance Exercises on Nonalcoholic Fatty Liver Disease
  Ju-Yeon Cho, Won Sohn
  Gut and Liver.2023; 17(4): 487.     CrossRef
• Comment on Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687
  Ludovico Abenavoli, Giuseppe La Torre, Natasa Milic
  Nutrients.2023; 15(13): 2907.     CrossRef
• Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD
  Nuria Perez-Diaz-del-Campo, Gabriele Castelnuovo, Chiara Rosso, Aurora Nicolosi, Marta Guariglia, Eleonora Dileo, Angelo Armandi, Gian Paolo Caviglia, Elisabetta Bugianesi
  Nutrients.2023; 15(13): 3018.     CrossRef
• Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
  Ho Soo Chun
  Gut and Liver.2023; 17(4): 485.     CrossRef
• From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
  Ming-Lun Yeh, Ming-Lung Yu
  Clinical and Molecular Hepatology.2023; 29(4): 969.     CrossRef
• Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
  Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
  Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
• Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity
  T.S. Krolevets, M.I. Syrovenko, M.A. Livzan
  Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43.     CrossRef
• Current epidemiology of chronic liver disease
  Richie Manikat, Aijaz Ahmed, Donghee Kim
  Gastroenterology Report.2023;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• An Update on Animal Models of Alcohol-Associated Liver Disease
  Peng Cao, Xiaojuan Chao, Hong-Min Ni, Wen-Xing Ding
  The American Journal of Pathology.2026; 196(1): 4.     CrossRef
• An Update on IL-22 Therapies in Alcohol-Associated Liver Disease and Beyond
  Lihong Fu, Burhan Yokus, Bin Gao, Pal Pacher
  The American Journal of Pathology.2026; 196(1): 136.     CrossRef
• Curcumol ameliorates alcohol and high-fat diet-induced fatty liver disease via modulation of the Ceruloplasmin/iron overload/mtDNA signaling pathway
  Tingting Ding, Wanqing Shen, Wenhui Tao, Junlu Peng, Meijun Pan, Xiaoyu Qi, Wanyu Feng, Na Wei, Shuguo Zheng, Huanhuan Jin
  The Journal of Nutritional Biochemistry.2025; 136: 109807.     CrossRef
• Establishment and application of murine models of alcoholic liver disease: A narrative review
  Mengsi Liu, Mingying Zhou, Xueyi Ren, Yandi Xie
  Alcohol, Clinical and Experimental Research.2025; 49(2): 271.     CrossRef
• Impact of binge drinking on alcoholic liver disease
  Jisoo Kang, Seol Hee Park, Mushira Khanam, Seo Bhin Park, Sumin Shin, Wonhyo Seo
  Archives of Pharmacal Research.2025;[Epub]     CrossRef
• Alcohol Consumption Amount, Drinking Pattern, and the Trajectory of Multimorbidity: A Prospective Cohort Study
  Weiqi Wang, Zhen Tian, Qiaoyu Wang, Qingrao Song, Yaxin Chen, Yuhua Song, Yuan Wang, Wanying Hou, Changhao Sun
  Molecular Nutrition & Food Research.2025;[Epub]     CrossRef
• Review Article: Impact of Alcohol Consumption on the Development and Progression of Metabolic Dysfunction–Associated Steatotic Liver Disease
  Yunxuan Lei, Yixuan Zhu, Wenjing Ni, Junping Shi, Wai‐Kay Seto, Jie Li
  Alimentary Pharmacology & Therapeutics.2025; 62(7): 680.     CrossRef
• Multiomic insights into the MPO-mediated NET formation pathway in alcohol-induced epilepsy risk
  Ningning Zhang, Sirui Chen, Jialing Jiang, Hong Jiang, Qing Wang, Srikrishnan Raju, Jackson G. Schumacher, Jiliang Lu, Yihe Lian, Yuansong Zhang, Yuanhang Xu, Lan Zhang, Yaqing Liu, Junqiang Li, Yiru Zhang, Yuxuan Wang, Yixue Gu, Tiancheng Wang, Xin Tian
  Genes & Diseases.2025; : 101917.     CrossRef
• Effects of Chronic Moderate Alcohol Intake on Metabolic Phenotypes and Gut Microbiota in Lean and Obese Mice with Distinct Dietary Structures
  Jiu-Jiao Gao, Zi-Die Nian, Ning Li, Tong Wang, Han Sun, Mei Tang, Jian-Rui Li, Biao Dong, Jing-Chen Xu, Yue Gong, Xin-Yue Liu, Jian-Dong Jiang, Hu Li, Zong-Gen Peng
  Nutrients.2025; 17(23): 3658.     CrossRef
• The ameliorative effect of turmeric (Curcuma longa Linn) extract and its major constituent, curcumin, and its analogs on ethanol toxicity
  Mahboobeh Ghasemzadeh Rahbardar, Hossein Hosseinzadeh
  Phytotherapy Research.2024; 38(5): 2165.     CrossRef
• Neutrophils in Cancer immunotherapy: friends or foes?
  Xueqin Huang, Eugenie Nepovimova, Vojtech Adam, Ladislav Sivak, Zbynek Heger, Marian Valko, Qinghua Wu, Kamil Kuca
  Molecular Cancer.2024;[Epub]     CrossRef
• Interaction between fatty acid oxidation and ethanol metabolism in liver
  Yongke Lu, Joseph George
  American Journal of Physiology-Gastrointestinal and Liver Physiology.2024; 326(5): G483.     CrossRef
• Sensitive Profiling of Mouse Liver Membrane Proteome Dysregulation Following a High‐Fat and Alcohol Diet Treatment
  Frank Antony, Zora Brough, Mona Orangi, Mohammed Al‐Seragi, Hiroyuki Aoki, Mohan Babu, Franck Duong van Hoa
  PROTEOMICS.2024;[Epub]     CrossRef
• Mitochondrial Dysfunction: At the Nexus between Alcohol-Associated Immunometabolic Dysregulation and Tissue Injury
  Robert W. Siggins, Patrick M. McTernan, Liz Simon, Flavia M. Souza-Smith, Patricia E. Molina
  International Journal of Molecular Sciences.2023; 24(10): 8650.     CrossRef
• Prevention of colitis-induced liver oxidative stress and inflammation in a transgenic mouse model with increased omega-3 polyunsaturated fatty acids
  Nadine Rohwer, Julia Jelleschitz, Annika Höhn, Daniela Weber, Anja A. Kühl, Chaoxuan Wang, Rei-Ichi Ohno, Nadja Kampschulte, Anne Pietzner, Nils Helge Schebb, Karsten-H. Weylandt, Tilman Grune
  Redox Biology.2023; 64: 102803.     CrossRef
• The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
  Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, Ramón Bataller, Marco Arrese
  Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 764.     CrossRef
• Dynamic Alterations to Hepatic MicroRNA-29a in Response to Long-Term High-Fat Diet and EtOH Feeding
  Tiebing Liang, Janaiah Kota, Kent E. Williams, Romil Saxena, Samer Gawrieh, Xiaoling Zhong, Teresa A. Zimmers, Naga Chalasani
  International Journal of Molecular Sciences.2023; 24(19): 14564.     CrossRef
• Independent and additive effects of binge drinking and obesity on liver enzymes: a cross-sectional analysis using the Korean National Health Insurance Service data
  Anthony Kityo, Sang-Ah Lee
  Gastroenterology Report.2023;[Epub]     CrossRef
• The interplay of Western diet and binge drinking on the onset, progression, and outlook of liver disease
  R Chris Skinner, Joel A Hagaman
  Nutrition Reviews.2022; 80(3): 503.     CrossRef
• Crosstalk between Oxidative Stress and Inflammatory Liver Injury in the Pathogenesis of Alcoholic Liver Disease
  Yoon Mee Yang, Ye Eun Cho, Seonghwan Hwang
  International Journal of Molecular Sciences.2022; 23(2): 774.     CrossRef
• Premorbid Steatohepatitis Increases the Seriousness of Dextran Sulfate Sodium-induced Ulcerative Colitis in Mice
  Meng-Yu Wang, Zi-Xuan Wang, Lei-Jie Huang, Rui-Xu Yang, Zi-Yuan Zou, Wen-Song Ge, Tian-Yi Ren, Jian-Gao Fan
  Journal of Clinical and Translational Hepatology.2022; 10(5): 847.     CrossRef
• Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease
  Julie Massart, Karima Begriche, Anne Corlu, Bernard Fromenty
  International Journal of Molecular Sciences.2022; 23(3): 1062.     CrossRef
• Alcoholic liver disease: a new insight into the pathogenesis of liver disease
  Seol Hee Park, Young-Sun Lee, Jaemin Sim, Seonkyung Seo, Wonhyo Seo
  Archives of Pharmacal Research.2022; 45(7): 447.     CrossRef
• Natural History of Alcohol-Associated Liver Disease: Understanding the Changing Landscape of Pathophysiology and Patient Care
  Jasmohan S. Bajaj, Laura E. Nagy
  Gastroenterology.2022; 163(4): 840.     CrossRef
• The effects of scoparone on alcohol and high-fat diet-induced liver injury revealed by RNA sequencing
  Min Wei, Ting Li, Houkang Cao, Haiyan He, Chaoyue Yang, Yifan Yin, Huijie Lu, Petr Novák, Kefeng Zhang, Ya Gao
  Biomedicine & Pharmacotherapy.2022; 155: 113770.     CrossRef
• Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease
  Luca Maccioni, Isabelle A. Leclercq, Bernd Schnabl, Peter Stärkel
  International Journal of Molecular Sciences.2021; 22(23): 12687.     CrossRef
• Alcohol Consumption Is Associated with Poor Prognosis in Obese Patients with COVID-19: A Mendelian Randomization Study Using UK Biobank
  Xiude Fan, Zhengwen Liu, Kyle L. Poulsen, Xiaoqin Wu, Tatsunori Miyata, Srinivasan Dasarathy, Daniel M. Rotroff, Laura E. Nagy
  Nutrients.2021; 13(5): 1592.     CrossRef
• The Role of Epigenetic Changes in the Progression of Alcoholic Steatohepatitis
  Hyeong Geug Kim, Jung-hyo Cho, Jeongkyu Kim, Seung-Jin Kim
  Frontiers in Physiology.2021;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomics
  Emily Flam, Joel T. Haas, Bart Staels
  Atherosclerosis.2025; 400: 119054.     CrossRef
• Multifaceted Interactions Between Bile Acids, Their Receptors, and MASH: From Molecular Mechanisms to Clinical Therapeutics
  Xuan Tang, Yuanjiao Zhou, Li Xia, Xiulian Lin, Yao Zhu, Menghan Chen, Jiayao Wang, Yamei Li
  Molecules.2025; 30(15): 3066.     CrossRef
• Dietary Omega-3 Fatty Acids from Fish and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Mediterranean Population: Findings from the NUTRIHEP Cohort
  Rossella Tatoli, Bonfiglio Caterina, Rossella Donghia, Pasqua Letizia Pesole, Luigi Fontana, Gianluigi Giannelli
  Nutrients.2025; 17(21): 3372.     CrossRef
• Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
  Tharani Senavirathna, Armaghan Shafaei, Ricky Lareu, Lois Balmer
  Antioxidants.2024; 13(4): 485.     CrossRef
• Effectiveness of the ALT/AST ratio for predicting insulin resistance in a Korean population: A large-scale, cross-sectional cohort study
  Seul Ki Han, Myung Jae Seo, Taesic Lee, Moon Young Kim, Anna Di Sessa
  PLOS ONE.2024; 19(5): e0303333.     CrossRef
• Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD
  I Sabinari, O Horakova, T Cajka, V Kleinova, MR Wieckowski, M Rossmeisl
  Physiological Research.2024; (Suppl 1): S295.     CrossRef
• Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
  Weiwei Dai, Baohong Xu, Peng Li, Junhua Weng
  American Journal of Therapeutics.2023; 30(1): e17.     CrossRef
• Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation
  Sonia Samuel, Ahmad Abulawi, Raza Malik
  Gastroenterology Insights.2023; 14(3): 249.     CrossRef
• Omega‐3 phospholipids and obesity‐associated NAFLD: Potential mechanisms and therapeutic perspectives
  Marko Mitrovic, Gabriella Sistilli, Olga Horakova, Martin Rossmeisl
  European Journal of Clinical Investigation.2022;[Epub]     CrossRef
• Enfermedad hepática grasa relacionada a trastornos metabólicos
  A. Fabrizzio Bardales Silva
  Revista Médica Basadrina.2022; 15(4): 85.     CrossRef
• Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: a matched case–control study
  Huai Zhang, Kenneth I. Zheng, Pei-Wu Zhu, Sui-Dan Chen, Gang Li, Hong-Lei Ma, Liang-Jie Tang, Ou-Yang Huang, Christopher D. Byrne, Giovanni Targher, Xiao-Dong Wang, Ming-Hua Zheng
  European Journal of Gastroenterology & Hepatology.2022; 34(8): 838.     CrossRef
• Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease
  Raghu Ramanathan, Ahmad Hassan Ali, Jamal A. Ibdah
  International Journal of Molecular Sciences.2022; 23(13): 7280.     CrossRef
• Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism
  Hongmei Yan, Weiyun Wu, Xinxia Chang, Mingfeng Xia, Sicheng Ma, Liu Wang, Jian Gao
  Biology of Sex Differences.2021;[Epub]     CrossRef
• Fructose intake is not associated to the risk of hepatic fibrosis in patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
  Vittoria Zambon Azevedo, Valesca Dall’Alba
  Clinical Nutrition.2021; 40(6): 4275.     CrossRef
• Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies
  Maryam Ebadi, Stephen Ip, Rahima A. Bhanji, Aldo J. Montano-Loza
  Nutrients.2021; 13(9): 3042.     CrossRef
• Association between the Severity of Nonalcoholic Fatty Liver Disease and the Risk of Coronary Artery Calcification
  Chien-Chih Chen, Wei-Chien Hsu, Han-Ming Wu, Jiun-Yi Wang, Pei-Yu Yang, I-Ching Lin
  Medicina.2021; 57(8): 807.     CrossRef
• Statins in Non-alcoholic Steatohepatitis
  Jose D. Torres-Peña, Laura Martín-Piedra, Francisco Fuentes-Jiménez
  Frontiers in Cardiovascular Medicine.2021;[Epub]     CrossRef
• Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases
  Robert J. Wong, Nandita Kachru, Diane J. Martinez, Meghan Moynihan, A. Burak Ozbay, Stuart C. Gordon
  Journal of Clinical Gastroenterology.2021; 55(10): 891.     CrossRef
• iTRAQ‑based quantitative proteomics analysis of the hepatoprotective effect of melatonin on ANIT‑induced cholestasis in rats
  Dingnan Wang, Han Yu, Yunzhou Li, Zongying Xu, Shaohua Shi, Dou Dou, Lili Sun, Zhili Zheng, Xinghua Shi, Xiulan Deng, Xianggen Zhong
  Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
• Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine
  Tingting Shi, Li Wu, Wenjun Ma, Liping Ju, Minghui Bai, Xiaowei Chen, Shourong Liu, Xingxin Yang, Junping Shi, Svein Haavik
  Evidence-Based Complementary and Alternative Medicine.2020;[Epub]     CrossRef
• Gut microbial fatty acid metabolites (KetoA and KetoC) affect the progression of nonalcoholic steatohepatitis and reverse cholesterol transport metabolism in mouse model
  Neng Tanty Sofyana, Jiawen Zheng, Yuki Manabe, Yuta Yamamoto, Shigenobu Kishino, Jun Ogawa, Tatsuya Sugawara
  Lipids.2020; 55(2): 151.     CrossRef
• Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View
  Rodrigo Valenzuela, Luis A. Videla
  Nutrients.2020; 12(2): 499.     CrossRef
• Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy
  Salvatore Petta, Jie Ting, Stefania Saragoni, Luca Degli Esposti, Sanatan Shreay, Maria Letizia Petroni, Giulio Marchesini
  Nutrition, Metabolism and Cardiovascular Diseases.2020; 30(6): 1014.     CrossRef
• Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database
  Jérôme Boursier, Sanatan Shreay, Cecile Fabron, Elodie Torreton, Jeremy Fraysse
  EClinicalMedicine.2020; 25: 100445.     CrossRef
• Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model
  Hwi-Jin Im, Seung-Ju Hwang, Jin-Seok Lee, Sung-Bae Lee, Ji-Yun Kang, Chang-Gue Son
  Nutrients.2020; 12(8): 2433.     CrossRef
• Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
  Soung Won Jeong
  Diabetes & Metabolism Journal.2020; 44(5): 640.     CrossRef
• Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research
  Clarissa Berardo, Laura Giuseppina Di Pasqua, Marta Cagna, Plinio Richelmi, Mariapia Vairetti, Andrea Ferrigno
  International Journal of Molecular Sciences.2020; 21(24): 9646.     CrossRef
• A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
  Amedeo Lonardo, Simonetta Lugari, Stefano Ballestri, Fabio Nascimbeni, Enrica Baldelli, Mauro Maurantonio
  Acta Diabetologica.2019; 56(4): 385.     CrossRef
• Ameliorative effect of Silybin on bisphenol A induced oxidative stress, cell proliferation and steroid hormones oxidation in HepG2 cell cultures
  Stefania Lama, Daniela Vanacore, Nadia Diano, Carla Nicolucci, Sonia Errico, Marcello Dallio, Alessandro Federico, Carmelina Loguercio, Paola Stiuso
  Scientific Reports.2019;[Epub]     CrossRef
• Docosahexaenoic acid and hydroxytyrosol co‐administration fully prevents liver steatosis and related parameters in mice subjected to high‐fat diet: A molecular approach
  Sandra A. Soto‐Alarcón, Macarena Ortiz, Paula Orellana, Francisca Echeverría, Andrés Bustamante, Alejandra Espinosa, Paola Illesca, Daniel Gonzalez‐Mañán, Rodrigo Valenzuela, Luis A. Videla
  BioFactors.2019; 45(6): 930.     CrossRef
• The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis
  Yan-Xiao Ji, Zan Huang, Xia Yang, Xiaozhan Wang, Ling-Ping Zhao, Pi-Xiao Wang, Xiao-Jing Zhang, Michele Alves-Bezerra, Lin Cai, Peng Zhang, Yue-Xin Lu, Lan Bai, Mao-Mao Gao, Huan Zhao, Song Tian, Yong Wang, Zhi-Xiang Huang, Xue-Yong Zhu, Yan Zhang, Jun Go
  Nature Medicine.2018; 24(2): 213.     CrossRef
• Prevention and management of gastroesophageal varices
  Yeon Seok Seo
  Clinical and Molecular Hepatology.2018; 24(1): 20.     CrossRef
• Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action
  Eleonora Scorletti, Christopher D. Byrne
  Molecular Aspects of Medicine.2018; 64: 135.     CrossRef
• NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?
  Subada Soti, Kathleen E. Corey, Jordan E. Lake, Kristine M. Erlandson
  Current HIV/AIDS Reports.2018; 15(3): 212.     CrossRef
• Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction
  Lucienne Juillerat-Jeanneret, John-David Aubert, Josip Mikulic, Dela Golshayan
  Journal of Medicinal Chemistry.2018; 61(22): 9811.     CrossRef
• Dietary Melatonin Supplementation Could Be a Promising Preventing/Therapeutic Approach for a Variety of Liver Diseases
  Francesca Bonomini, Elisa Borsani, Gaia Favero, Luigi F. Rodella, Rita Rezzani
  Nutrients.2018; 10(9): 1135.     CrossRef

Citations

Citations to this article as recorded by  

• Genetic variants underlying precancerous conditions of hepatocellular carcinoma
  Jonathan Jaime G. Guerrero, Paolo C. Encarnacion, Mark Angelo S. del Rosario, Matthew Aldren S. Ora, Jiayan Zhou, Kin Israel Notarte, Wan‐Chun Li, Ching‐Wen Chang
  International Journal of Cancer.2026; 158(3): 488.     CrossRef
• Global Epidemiological Impact of PNPLA3 I148M on Liver Disease
  Julia Kozlitina, Silvia Sookoian
  Liver International.2025;[Epub]     CrossRef
• Statin‐associated regulation of hepatic PNPLA3 in patients without known liver disease
  Osman Ahmed, Vladimir S. Shavva, Laura Tarnawski, Wanmin Dai, Filip Borg, Viggo V. Olofsson, Ting Liu, Peter Saliba‐Gustafsson, Christian Simini, Matteo Pedrelli, Otto Bergman, Giuseppe Danilo Norata, Paolo Parini, Anders Franco‐Cereceda, Per Eriksson, St
  Journal of Internal Medicine.2025; 297(1): 47.     CrossRef
• Newly identified single-nucleotide polymorphism associated with the transition from nonalcoholic fatty liver disease to liver fibrosis: results from a nested case-control study in the UK biobank
  Yitong Ling, Yu Xuan Yang, Yan Chun Chen, Jing Hao Wang, Dong Ge Feng, Shi Jian Xiang, Xiaoyu Zhang, Jun Lyu, Sha Sha Li
  Annals of Medicine.2025;[Epub]     CrossRef
• Genome-wide association study of the fatty liver index in the Taiwanese population reveals shared and population-specific genetic risk factors across ethnicities
  Pei Pei Lau, Chun-Yu Wei, Min-Rou Lin, Wan-Hsuan Chou, Yu-Jui Yvonne Wan, Wei-Chiao Chang
  Cell & Bioscience.2025;[Epub]     CrossRef
• Fishing for Solutions: How Pre‐Conceptional Fish Oil Supplementation in Obese Fathers Reduces Risk of Non‐Alcoholic Fatty Liver Disease in Offspring Mice
  Junhui Yang, Akriti Shrestha, Latha Ramalingam
  Molecular Nutrition & Food Research.2025;[Epub]     CrossRef
• Genetic and metabolic characterization of individual differences in liver fat accumulation in Atlantic salmon
  Siri S. Horn, Anna K. Sonesson, Aleksei Krasnov, Muhammad L. Aslam, Borghild Hillestad, Bente Ruyter
  Frontiers in Genetics.2025;[Epub]     CrossRef
• Urinary biomarkers of drinking water disinfection byproducts in relation to blood-based liver function parameters among reproductive-aged Chinese women
  Ping-Ping Gui, Yan-Ling Deng, Min Zhang, Yu Miao, Peng-Hui Liu, Jia-Yue Zeng, Yang Wu, Cheng-Ru Li, Xiao-Ying Liu, Yang-Juan Li, Jin-Qin Zhu, A-Xue Liu, Bin Zhou, Fei Yang, Qiang Zeng
  Science of The Total Environment.2025; 970: 179016.     CrossRef
• The correlation between the polymorphism of lysolecithin acyltransferase (MBOAT7) rs641738 and liver fibrosis
  Yuxia Yang, Xiang Chen, Huiqin Zhang, Gang Yang, Xiaoyun Zhu, Xiujing Si, Feilong Chen, Yan Zhao, Feng Jin, Juanjuan Lu
  Personalized Medicine.2025; 22(2): 113.     CrossRef
• Weight loss in MASLD restores the balance of liver fatty acid sources
  Jennifer E. Lambert, Maria A. Ramos-Roman, Maressa J. Valdez, Jeffrey D. Browning, Thomas Rogers, Elizabeth J. Parks
  Journal of Clinical Investigation.2025;[Epub]     CrossRef
• Ppp1r3b is a metabolic switch that shifts hepatic energy storage from lipid to glycogen
  Kate Townsend Creasy, Minal B. Mehta, Carolin V. Schneider, Joseph Park, David Zhang, Swapnil V. Shewale, John S. Millar, Marijana Vujkovic, Nicholas J. Hand, Paul M. Titchenell, Joseph A. Baur, Daniel J. Rader
  Science Advances.2025;[Epub]     CrossRef
• Parental liver disease mortality is associated with unfavorable outcomes in patients with alcohol-associated hepatitis
  Wanzhu Tu, Samer Gawrieh, Lauren Nephew, Craig McClain, Qing Tang, Srinivasan Dasarathy, Vatsalya Vatsalya, Douglas A. Simonetto, Carla Kettler, Gyongyi Szabo, Bruce Barton, Yunpeng Yu, Patrick S. Kamath, Arun J. Sanyal, Laura Nagy, Mack C. Mitchell, Suth
  Hepatology Communications.2025;[Epub]     CrossRef
• Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
  Daniel Clayton-Chubb, William W. Kemp, Ammar Majeed, Peter W. Lange, Jessica A. Fitzpatrick, Karl Vaz, John S. Lubel, Alexander D. Hodge, Joanne Ryan, John J. McNeil, Alice J. Owen, Robyn L. Woods, Stuart K. Roberts
  Nutrients.2025; 17(13): 2189.     CrossRef
• Sex Differences in the Association Between the Korean Healthy Eating Index and Liver Enzymes Among Korean Adults
  Seong-Uk Baek, Jin-Ha Yoon
  Nutrients.2025; 17(14): 2372.     CrossRef
• Genetic Variants, Metabolic Dysfunction-Associated Fatty Liver Disease, and Major Health Outcomes in Older Adults
  Daniel Clayton-Chubb, Ammar Majeed, William W. Kemp, Chenglong Yu, Peter W. Lange, Jessica A. Fitzpatrick, Robyn L. Woods, Andrew M. Tonkin, Andrew T. Chan, Mark R. Nelson, Joanne Ryan, Alexander D. Hodge, John S. Lubel, Hans G. Schneider, John J. McNeil,
  Biomedicines.2025; 13(8): 1977.     CrossRef
• Genetic determinants of hepatocellular carcinoma: role of PNPLA3, FABP2, FADS1/FADS2 genes in Yakuts
  Nadezhda I. Pavlova, Alexey V. Krylov, Alexey A. Bochurov, Ivan P. Troev, Khariton A. Kurtanov
  Russian Journal of Oncology.2025; 30(2): 114.     CrossRef
• Increased 1-deoxysphingolipids caused by an altered plasma alanine to serine ratio are associated with metabolic dysfunction-associated steatotic liver disease (MASLD)
  F. Wipfli, M. A. Lone, A. von Eckardstein, A. Verrijken, S. Francque, J. Weyler, L. Van Gaal, B. Staels, T. Hornemann
  Metabolomics.2025;[Epub]     CrossRef
• Heavy Metals, Gut Microbiota, and Biochemical Markers: Unraveling the Complexities of Obesity
  Ahmed Basim Mohamed Alamer, Majid Komijani, Shahnaz Shahrjerdi
  MicrobiologyOpen.2025;[Epub]     CrossRef
• From “MAFLD” to “MASLD”: Was This Revolution Worth It? A Head-to-Head Comparison of MAFLD and MASLD Criteria in Estimating Liver Disease Progression and Cardiovascular Risk in Real Life
  Marcello Dallio, Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Claudio Basile, Annachiara Coppola, Alessia Silvestrin, Giusy Senese, Marco Niosi, Alessandro Federico
  Livers.2025; 5(4): 58.     CrossRef
• A PNPLA3 gén rs738409 variánsának jelentősége metabolikus diszfunkcióhoz társult steatoticus májbetegségben
  Ákos Nádasdi, Gábor Firneisz
  Orvosi Hetilap.2025; 166(47): 1843.     CrossRef
• Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style
  Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan
  Steroids.2024; 203: 109330.     CrossRef
• Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
  Maurizio Parola, Massimo Pinzani
  Molecular Aspects of Medicine.2024; 95: 101231.     CrossRef
• The pathophysiology of MASLD: an immunometabolic perspective
  Julian Schwärzler, Felix Grabherr, Christoph Grander, Timon E. Adolph, Herbert Tilg
  Expert Review of Clinical Immunology.2024; 20(4): 375.     CrossRef
• Genetic predisposition to metabolic dysfunction-associated fatty liver disease
  O.E. Abaturov, A.O. Nikulina
  CHILD`S HEALTH.2024; 19(3): 162.     CrossRef
• Whole-Exome Sequencing (WES) Reveals Novel Sex-Specific Gene Variants in Non-Alcoholic Steatohepatitis (MASH)
  Jing Wei, Boyang Jason Wu, Sayed S. Daoud
  Genes.2024; 15(3): 357.     CrossRef
• Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort
  Huiyul Park, Eileen L. Yoon, Goh Eun Chung, Eun Kyung Choe, Jung Ho Bae, Seung Ho Choi, Mimi Kim, Woochang Hwang, Hye-Lin Kim, Sun Young Yang, Dae Won Jun
  Gut and Liver.2024; 18(2): 316.     CrossRef
• Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR Variants to MASLD Severity in an Egyptian Population
  Nehal Elmansoury, Ahmed A. Megahed, Ahmed Kamal, Nefertiti El-Nikhely, Marina Labane, Manal Abdelmageed, Ann K. Daly, Ahmed Wahid
  Genes.2024; 15(4): 455.     CrossRef
• Probiotics—A Promising Novel Therapeutic Approach in the Management of Chronic Liver Diseases
  Gokulapriya Ramachandran, Biju Pottakkat
  Journal of Medicinal Food.2024; 27(6): 467.     CrossRef
• Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
  Maja Thiele, Ida Falk Villesen, Lili Niu, Stine Johansen, Karolina Sulek, Suguru Nishijima, Lore Van Espen, Marisa Keller, Mads Israelsen, Tommi Suvitaival, Andressa de Zawadzki, Helene Bæk Juel, Maximilian Joseph Brol, Sara Elizabeth Stinson, Yun Huang,
  Journal of Hepatology.2024; 81(2): 345.     CrossRef
• The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum
  Paulina Vidal-Cevallos, Adriana P. Sorroza-Martínez, Norberto C. Chávez-Tapia, Misael Uribe, Eduardo E. Montalvo-Javé, Natalia Nuño-Lámbarri
  International Journal of Molecular Sciences.2024; 25(8): 4397.     CrossRef
• Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics
  Rebecca L. Koch, James B. Stanton, Susan McClatchy, Gary A. Churchill, Steven W. Craig, Darian N. Williams, Mallory E. Johns, Kylah R. Chase, Dana L. Thiesfeldt, Jessica C. Flynt, Robert Pazdro
  Redox Biology.2024; 75: 103248.     CrossRef
• Human iPSC-derived liver co-culture spheroids to model liver fibrosis
  Laura Cools, Mina Kazemzadeh Dastjerd, Ayla Smout, Vincent Merens, Yuwei Yang, Hendrik Reynaert, Nouredin Messaoudi, Vincent De Smet, Manoj Kumar, Stefaan Verhulst, Catherine Verfaillie, Leo A van Grunsven
  Biofabrication.2024; 16(3): 035032.     CrossRef
• Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease
  Mohamed N. Abdelnabi, Ghada S. Hassan, Naglaa H. Shoukry
  Frontiers in Immunology.2024;[Epub]     CrossRef
• Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries
  Ehsan Amini-Salehi, Negin Letafatkar, Naeim Norouzi, Farahnaz Joukar, Arman Habibi, Mona Javid, Nazila Sattari, Mehrdad Khorasani, Ali Farahmand, Shervin Tavakoli, Behnaz Masoumzadeh, Elaheh Abbaspour, Sahand Karimzad, Amir Ghadiri, Gautam Maddineni, Moha
  Archives of Medical Research.2024; 55(6): 103043.     CrossRef
• The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment
  Gautam Maddineni, Sri J. Obulareddy, Ruchir D. Paladiya, Rohan R. Korsapati, Shika Jain, Herby Jeanty, Fnu Vikash, Nayanika C. Tummala, Samatha Shetty, Arezoo Ghazalgoo, Abinash Mahapatro, Viswanadh Polana, Dhruvan Patel
  Annals of Medicine & Surgery.2024; 86(8): 4714.     CrossRef
• Advances in our understanding of the molecular heterogeneity of fatty liver disease: towards informed treatment decision making
  Carlos J Pirola, Silvia Sookoian
  Expert Review of Gastroenterology & Hepatology.2023;[Epub]     CrossRef
• Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
  Silvia Sookoian, Carlos J. Pirola
  Clinical and Molecular Hepatology.2023; 29(Suppl): S184.     CrossRef
• The association of non‐alcoholic fatty liver disease between parents and adolescent children
  Yewan Park, Dong Hyun Sinn, Kyunga Kim, Geum‐Youn Gwak
  Alimentary Pharmacology & Therapeutics.2023; 57(2): 245.     CrossRef
• Editorial: ‘Talis pater, talis filius’
  Natalia Rosso, Claudio Tiribelli
  Alimentary Pharmacology & Therapeutics.2023; 57(1): 171.     CrossRef
• NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials
  Omar E. Hegazi, Samer O. Alalalmeh, Ghala Rashid Humaid Alnuaimi, Moyad Shahwan, Ammar Abdulrahman Jairoun, Nasser M. Alorfi, Shaker A. Majrashi, Mustfa Faisal Alkhanani, Abdullah Alkhattabi, Mansour M. Alourfi, Faris A. Alsolami, Saeed Alsharif, Hatim Al
  Frontiers in Medicine.2023;[Epub]     CrossRef
• Using epigenomics to understand cellular responses to environmental influences in diseases
  Julia J. Wattacheril, Srilakshmi Raj, David A. Knowles, John M. Greally, Gregory P. Copenhaver
  PLOS Genetics.2023; 19(1): e1010567.     CrossRef
• Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
  Daniel Clayton-Chubb, William Kemp, Ammar Majeed, John S. Lubel, Alex Hodge, Stuart K. Roberts
  Nutrients.2023; 15(3): 687.     CrossRef
• Lack of GPR180 ameliorates hepatic lipid depot via downregulation of mTORC1 signaling
  Ken Yoshida, Kazuha Yokota, Kazuhisa Watanabe, Hidetoshi Tsuda, Ayumi Matsumoto, Hiroaki Mizukami, Sadahiko Iwamoto
  Scientific Reports.2023;[Epub]     CrossRef
• TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a “Prudent” Dietary Pattern on Serum Triglyceride Levels
  Ioanna Panagiota Kalafati, Maria Dimitriou, Konstantinos Revenas, Alexander Kokkinos, Panos Deloukas, George V. Dedoussis
  Nutrients.2023; 15(5): 1112.     CrossRef
• Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation
  Neda Yahoo, Michael Dudek, Percy Knolle, Mathias Heikenwälder
  Journal of Hepatology.2023; 79(2): 538.     CrossRef
• Genetic Markers Predisposing to Nonalcoholic Steatohepatitis
  Aalam Sohal, Hunza Chaudhry, Kris V. Kowdley
  Clinics in Liver Disease.2023; 27(2): 333.     CrossRef
• The potential of integrating human and mouse discovery platforms to advance our understanding of cardiometabolic diseases
  Aaron W Jurrjens, Marcus M Seldin, Corey Giles, Peter J Meikle, Brian G Drew, Anna C Calkin
  eLife.2023;[Epub]     CrossRef
• Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons
  Michael H. Le, David M. Le, Thomas C. Baez, Yuankai Wu, Takanori Ito, Eunice Y. Lee, KeeSeok Lee, Christopher D. Stave, Linda Henry, Scott D. Barnett, Ramsey Cheung, Mindie H. Nguyen
  Journal of Hepatology.2023; 79(2): 287.     CrossRef
• Diversitätsfaktoren in der Gastroenterologie
  Teresa Hof, Robert Thimme, Peter Hasselblatt
  DMW - Deutsche Medizinische Wochenschrift.2023; 148(09): 519.     CrossRef
• A Review of the Effects of Fucoxanthin on NAFLD
  Nor Hafiza Sayuti, Khairul Najmi Muhammad Nawawi, Jo Aan Goon, Norfilza Mohd Mokhtar, Suzana Makpol, Jen Kit Tan
  Nutrients.2023; 15(8): 1954.     CrossRef
• Blood lactate levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study
  Yi-Lin Ma, Jiang-Feng Ke, Jun-Wei Wang, Yu-Jie Wang, Man-Rong Xu, Lian-Xi Li
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• High fat in blood and body and increased risk of clinically diagnosed non-alcoholic fatty liver disease in 105,981 individuals
  Lærke Kristine Kyhl, Børge Grønne Nordestgaard, Anne Tybjærg-Hansen, Sune Fallgaard Nielsen
  Atherosclerosis.2023; 376: 1.     CrossRef
• Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease
  Nicholas Darci-Maher, Marcus Alvarez, Uma Thanigai Arasu, Ilakya Selvarajan, Seung Hyuk T. Lee, David Z. Pan, Zong Miao, Sankha Subhra Das, Dorota Kaminska, Tiit Örd, Jihane N. Benhammou, Martin Wabitsch, Joseph R. Pisegna, Ville Männistö, Kirsi H. Pietil
  eBioMedicine.2023; 92: 104620.     CrossRef
• Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
  Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, Monika Różycka-Kosmalska, Tadeusz Pietras, Kasper Sipowicz, Marcin Kosmalski
  International Journal of Molecular Sciences.2023; 24(11): 9677.     CrossRef
• Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study
  Amirhossein Naghipour, Ehsan Amini-Salehi, Mahdi Orang Gorabzarmakhi, Milad Shahdkar, Bahman Fouladi, Iraj Alipourfard, Zahra Momayez Sanat
  Systematic Reviews.2023;[Epub]     CrossRef
• Prospects of evolution-based artificial intelligence models in genome-wide studies to stratify genetic risk variants in nonalcoholic fatty liver disease
  Helen Huang, Wireko A. Awuah, Tulika Garg, Jyi Cheng Ng, Aashna Mehta, Krishna Ramamoorthy, Jacob Kalmanovich, Mohammad M. Hasan
  Annals of Medicine & Surgery.2023; 85(6): 2743.     CrossRef
• Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
  Saumya Madushani Samarasinghe, Asanka Sudeshini Hewage, Rohan Chaminda Siriwardana, Kamani Hemamala Tennekoon, Madunil Anuk Niriella, Sumadee De Silva
  Egyptian Journal of Medical Human Genetics.2023;[Epub]     CrossRef
• Role of Matrix Gla Protein in Transforming Growth Factor-β Signaling and Nonalcoholic Steatohepatitis in Mice
  Simon T. Hui, Lili Gong, Chantle Swichkow, Montgomery Blencowe, Dorota Kaminska, Graciel Diamante, Calvin Pan, Meet Dalsania, Samuel W. French, Clara E. Magyar, Päivi Pajukanta, Jussi Pihlajamäki, Kristina I. Boström, Xia Yang, Aldons J. Lusis
  Cellular and Molecular Gastroenterology and Hepatology.2023; 16(6): 943.     CrossRef
• Usefulness of PNPLA3 variant for predicting hepatic events in steatotic liver disease: a matter of ethnicity or baseline risk?
  Umberto Vespasiani‐Gentilucci, Luca Valenti, Stefano Romeo
  Liver International.2023; 43(10): 2052.     CrossRef
• New horizons of human genetics in digestive diseases
  Lanlan Chen, Guoyue Lv
  eGastroenterology.2023; 1(2): e100029.     CrossRef
• Microbiome and Genetic Factors in the Pathogenesis of Liver Diseases
  Dimitrina Miteva, Monika Peshevska-Sekulovska, Violeta Snegarova, Milena Peruhova, Georgi H. Vasilev, Georgi V. Vasilev, Metodija Sekulovski, Snezhina Lazova, Milena Gulinac, Latchezar Tomov, Antoaneta Mihova, Tsvetelina Velikova
  Gastroenterology Insights.2023; 14(4): 575.     CrossRef
• Prevalence of Nonalcoholic Fatty Liver Disease in Hypothyroid Subjects: A Cross-sectional Comparative Study
  Maharshi Patel, Sourya Acharya, Sunil Kumar
  Indian Journal of Medical Specialities.2023; 14(3): 145.     CrossRef
• Epigenetics factors in nonalcoholic fatty liver disease
  Carlos Jose Pirola, Silvia Sookoian
  Expert Review of Gastroenterology & Hepatology.2022; 16(6): 521.     CrossRef
• Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non‐alcoholic fatty liver disease in children
  Kyung Jae Lee, Jin Soo Moon, Nan Young Kim, Jae Sung Ko
  Pediatric Obesity.2022;[Epub]     CrossRef
• A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores
  Antonio De Vincentis, Federica Tavaglione, Oveis Jamialahmadi, Antonio Picardi, Raffaele Antonelli Incalzi, Luca Valenti, Stefano Romeo, Umberto Vespasiani-Gentilucci
  Clinical Gastroenterology and Hepatology.2022; 20(3): 658.     CrossRef
• Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank
  Antonio De Vincentis, Federica Tavaglione, Rocco Spagnuolo, Roberta Pujia, Dario Tuccinardi, Gianluca Mascianà, Antonio Picardi, Raffaele Antonelli Incalzi, Luca Valenti, Stefano Romeo, Umberto Vespasiani-Gentilucci
  International Journal of Obesity.2022; 46(3): 486.     CrossRef
• Genome‐Wide Association Study of NAFLD Using Electronic Health Records
  Cameron J. Fairfield, Thomas M. Drake, Riinu Pius, Andrew D. Bretherick, Archie Campbell, David W. Clark, Jonathan A. Fallowfield, Caroline Hayward, Neil C. Henderson, Peter K. Joshi, Nicholas L. Mills, David J. Porteous, Prakash Ramachandran, Robert K. S
  Hepatology Communications.2022; 6(2): 297.     CrossRef
• Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease
  Abhinav Anand, Amit A. Singh, Anshuman Elhence, Manas Vaishnav, Sagnik Biswas, Deepak Gunjan, Shivanand R. Gamanagatti, Baibaswata Nayak, Ramesh Kumar, Shalimar
  Journal of Clinical and Experimental Hepatology.2022; 12(2): 362.     CrossRef
• Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients
  Karla Sawada Toda-Oti, José Tadeu Stefano, Ana Mercedes Cavaleiro, Flair José Carrilho, Maria Lúcia Correa-Gianella, Cláudia Pinto Marques de Souza de Oliveira
  Metabolic Syndrome and Related Disorders.2022; 20(2): 114.     CrossRef
• Metabolism and Health Effects of Rare Sugars in a CACO-2/HepG2 Coculture Model
  Amar van Laar, Charlotte Grootaert, Filip Van Nieuwerburgh, Dieter Deforce, Tom Desmet, Koen Beerens, John Van Camp
  Nutrients.2022; 14(3): 611.     CrossRef
• Early Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease
  露文 李
  Advances in Clinical Medicine.2022; 12(02): 986.     CrossRef
• Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico
  Paulina Vidal‐Cevallos, Aldo Torre, Nahum Mendez‐Sanchez, Misael Uribe, Norberto C. Chavez‐Tapia
  Clinical Liver Disease.2022; 19(2): 68.     CrossRef
• The association between rs1260326 with the risk of NAFLD and the mediation effect of triglyceride on NAFLD in the elderly Chinese Han population
  Fan Yuan, Zhan Gu, Yan Bi, Ruixue Yuan, Weibo Niu, Decheng Ren, Lei Zhang, Guang He, Bao-Cheng Liu
  Aging.2022; 14(6): 2736.     CrossRef
• Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)
  Laura Valenzuela-Vallejo, Christos S. Mantzoros
  Metabolism.2022; 134: 155246.     CrossRef
• Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease
  Raghu Ramanathan, Ahmad Hassan Ali, Jamal A. Ibdah
  International Journal of Molecular Sciences.2022; 23(13): 7280.     CrossRef
• African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population
  Lourianne Nascimento Cavalcante, Jun Porto, Daniel Mazo, Adhemar Longatto-Filho, José Tadeu Stefano, Andre Castro Lyra, Flair Jose Carrilho, Rui Manuel Reis, Venâncio A.F. Alves, Arun J. Sanyal, Claudia P Oliveira
  Annals of Hepatology.2022; 27(6): 100728.     CrossRef
• A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation
  Marijana Vujkovic, Shweta Ramdas, Kim M. Lorenz, Xiuqing Guo, Rebecca Darlay, Heather J. Cordell, Jing He, Yevgeniy Gindin, Chuhan Chung, Robert P. Myers, Carolin V. Schneider, Joseph Park, Kyung Min Lee, Marina Serper, Rotonya M. Carr, David E. Kaplan, M
  Nature Genetics.2022; 54(6): 761.     CrossRef
• The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
  Magdalena Rausch, Sophia L. Samodelov, Michele Visentin, Gerd A. Kullak-Ublick
  International Journal of Molecular Sciences.2022; 23(22): 13967.     CrossRef
• Multifaceted Clinical Research on Obesity-related Disease Prevention Focusing on the DsbA-L Gene
  Kentaro Oniki
  YAKUGAKU ZASSHI.2022; 142(11): 1177.     CrossRef
• Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines
  Anwesha Gangopadhyay, Radwa Ibrahim, Karli Theberge, Meghan May, Karen L. Houseknecht
  Frontiers in Neuroscience.2022;[Epub]     CrossRef
• Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
  Damien Chua, Zun Siong Low, Guo Xiang Cheam, Aik Seng Ng, Nguan Soon Tan
  International Journal of Molecular Sciences.2022; 23(23): 14762.     CrossRef
• Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
  Kiarash Riazi, Mark G. Swain, Stephen E. Congly, Gilaad G. Kaplan, Abdel-Aziz Shaheen
  Nutrients.2022; 14(21): 4556.     CrossRef
• Comprehensive analysis of the translatome reveals the relationship between the translational and transcriptional control in high fat diet-induced liver steatosis
  Zupeng Luo, Hailong Hu, Siqi Liu, Zhiwang Zhang, Yixing Li, Lei Zhou
  RNA Biology.2021; 18(6): 863.     CrossRef
• The gut mycobiome: a novel player in chronic liver diseases
  Lu Jiang, Peter Stärkel, Jian-Gao Fan, Derrick Eugene Fouts, Petra Bacher, Bernd Schnabl
  Journal of Gastroenterology.2021; 56(1): 1.     CrossRef
• Flavin Adenine Dinucleotide Depletion Caused by electron transfer flavoprotein subunit alpha Haploinsufficiency Leads to Hepatic Steatosis and Injury in Zebrafish
  Ki‐Hoon Park, Monika Gooz, Zhi‐Wei Ye, Jie Zhang, Gyda C. Beeson, Don C. Rockey, Seok‐Hyung Kim
  Hepatology Communications.2021; 5(6): 976.     CrossRef
• Defining NASH from a Multi-Omics Systems Biology Perspective
  Lili Niu, Karolina Sulek, Catherine G. Vasilopoulou, Alberto Santos, Nicolai J. Wewer Albrechtsen, Simon Rasmussen, Florian Meier, Matthias Mann
  Journal of Clinical Medicine.2021; 10(20): 4673.     CrossRef
• Changes in liver steatosis in HIV-positive women are associated with the BMI, but not with biomarkers
  Rafael Fernandez-Botran, Michael W. Plankey, Deanna Ware, José Bordon
  Cytokine.2021; 144: 155573.     CrossRef
• Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities
  Xiaomi Du, Natalie DeForest, Amit R. Majithia
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort
  Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed
  Clinical and Molecular Hepatology.2021; 27(3): 486.     CrossRef
• Genetic risk scores and personalization of care in fatty liver disease
  Cristiana Bianco, Federica Tavaglione, Stefano Romeo, Luca Valenti
  Current Opinion in Pharmacology.2021; 61: 6.     CrossRef
• Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
  David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
  Journal of Korean Medical Science.2021;[Epub]     CrossRef
• Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease
  Taekyeong Yoo, Sae Kyung Joo, Hyo Jung Kim, Hyun Young Kim, Hyungtai Sim, Jieun Lee, Hee-Hoon Kim, Sunhee Jung, Youngha Lee, Oveis Jamialahmadi, Stefano Romeo, Won-Il Jeong, Geum-Sook Hwang, Keon Wook Kang, Jae Woo Kim, Won Kim, Murim Choi
  Journal of Hepatology.2021; 75(3): 514.     CrossRef
• The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under in vitro conditions
  Safa Tahmasebi, Hassan Neishaboori, Davood Jafari, Elham Faghihzadeh, Abdolreza Esmaeilzadeh, Abbas Mirshafiey
  Immunopharmacology and Immunotoxicology.2021; 43(5): 562.     CrossRef
• Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
  Cristina Piras, Antonio Noto, Luciano Ibba, Martino Deidda, Vassilios Fanos, Sandro Muntoni, Vera Piera Leoni, Luigi Atzori
  Metabolites.2021; 11(10): 694.     CrossRef
• Sirtuin3 rs28365927 functional variant confers to the high risk of non-alcoholic fatty liver disease in Chinese Han population
  Li-jie Chen, Jing Guo, Song-xia Zhang, Ying Xu, Qing Zhao, Wei Zhang, Jian Xiao, Yao Chen
  Lipids in Health and Disease.2021;[Epub]     CrossRef
• Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
  João V. S. Guerra, Marieli M. G. Dias, Anna J. V. C. Brilhante, Maiara F. Terra, Marta García-Arévalo, Ana Carolina M. Figueira
  Nutrients.2021; 13(8): 2830.     CrossRef
• Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis
  Matthias Bartneck
  Advanced Drug Delivery Reviews.2021; 173: 70.     CrossRef
• Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
  Madhangi Parameswaran, Hamzah A Hasan, Jafor Sadeque, Sharan Jhaveri, Chaithanya Avanthika, Abimbola E Arisoyin, Maulik B Dhanani, Swaroopa M Rath
  Cureus.2021;[Epub]     CrossRef
• Racial differences in prevalence and severity of non-alcoholic fatty liver disease
  Maurizio Bonacini, Farah Kassamali, Swathi Kari, Nieves Lopez Barrera, Mohamed Kohla
  World Journal of Hepatology.2021; 13(7): 763.     CrossRef
• Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease
  Dong Hyun Sinn, Danbee Kang, Soo Jin Cho, Seung Woon Paik, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak
  European Journal of Gastroenterology & Hepatology.2021; 33(1S): e529.     CrossRef
• Non‐alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study
  Dong Hyun Sinn, Danbee Kang, Yoosoo Chang, Seungho Ryu, Soo Jin Cho, Seung Woon Paik, Young Bin Song, Roberto Pastor‐Barriuso, Eliseo Guallar, Juhee Cho, Geum‐Youn Gwak
  Journal of Gastroenterology and Hepatology.2020; 35(5): 833.     CrossRef
• Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
  Mohammed Eslam, Jacob George
  Nature Reviews Gastroenterology & Hepatology.2020; 17(1): 40.     CrossRef
• Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study
  Jeong-Ju Yoo, Yang Jae Yoo, Woo Ram Moon, Seung Up Kim, Soung Won Jeong, Ha Na Park, Min Gyu Park, Jae Young Jang, Su Yeon Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Sang Gyune Kim, Young Seok Kim, Ji Hoon Kim, Jong
  The Korean Journal of Internal Medicine.2020; 35(6): 1346.     CrossRef
• Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis
  Johanna K. DiStefano
  Cellular and Molecular Life Sciences.2020; 77(11): 2079.     CrossRef
• Evolution of NAFLD and Its Management
  Manpreet S. Mundi, Saketh Velapati, Janki Patel, Todd A. Kellogg, Barham K. Abu Dayyeh, Ryan T. Hurt
  Nutrition in Clinical Practice.2020; 35(1): 72.     CrossRef
• Liver involvement in patients with Gaucher disease types I and III
  Rodrigo Tzovenos Starosta, Filippo Pinto e Vairo, Alícia Dorneles Dornelles, Suélen Porto Basgalupp, Marina Siebert, Maria Lúcia Alves Pedroso, Carlos Thadeu Schmidt Cerski, Mário Reis Álvares-da-Silva, Ida Vanessa Doederlein Schwartz
  Molecular Genetics and Metabolism Reports.2020; 22: 100564.     CrossRef
• NETGE-PLUS: Standard and Network-Based Gene Enrichment Analysis in Human and Model Organisms
  Samuele Bovo, Pier Luigi Martelli, Pietro Di Lena, Rita Casadio
  Journal of Proteome Research.2020; 19(7): 2873.     CrossRef
• Complications, morbidity and mortality of nonalcoholic fatty liver disease
  Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, Anna Alisi, Christopher D. Byrne, Giovanni Targher
  Metabolism.2020; 111: 154170.     CrossRef
• Genetic Risk for Hepatic Fat among an Ethnically Diverse Cohort of Youth: The Exploring Perinatal Outcomes among Children Study
  Maggie A. Stanislawski, Jessica Shaw, Elizabeth Litkowski, Ethan M. Lange, Wei Perng, Dana Dabelea, Leslie A. Lange
  The Journal of Pediatrics.2020; 220: 146.     CrossRef
• Patatin‐Like Phospholipase Domain‐Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population
  Aynur Unalp‐Arida, Constance E. Ruhl
  Hepatology.2020; 71(3): 820.     CrossRef
• Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis?
  Hyuk Soo Eun
  Clinical and Molecular Hepatology.2020; 26(2): 236.     CrossRef
• MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
  Mohammed Eslam, Arun J. Sanyal, Jacob George, Arun Sanyal, Brent Neuschwander-Tetri, Claudio Tiribelli, David E. Kleiner, Elizabeth Brunt, Elisabetta Bugianesi, Hannele Yki-Järvinen, Henning Grønbæk, Helena Cortez-Pinto, Jacob George, Jiangao Fan, Luca Va
  Gastroenterology.2020; 158(7): 1999.     CrossRef
• Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis
  Tracey Hurrell, Vlasia Kastrinou-Lampou, Achilleas Fardellas, Delilah F. G. Hendriks, Åsa Nordling, Inger Johansson, Audrey Baze, Céline Parmentier, Lysiane Richert, Magnus Ingelman-Sundberg
  Cells.2020; 9(4): 964.     CrossRef
• Genome‐Wide Association Study of Lean Nonalcoholic Fatty Liver Disease Suggests Human Leukocyte Antigen as a Novel Candidate Locus
  Ken Yoshida, Kazuha Yokota, Yukinobu Kutsuwada, Kazuhiro Nakayama, Kazuhisa Watanabe, Ayumi Matsumoto, Hiroshi Miyashita, Seik‐soon Khor, Katsushi Tokunaga, Yosuke Kawai, Masao Nagasaki, Sadahiko Iwamoto
  Hepatology Communications.2020; 4(8): 1124.     CrossRef
• Genome‐Wide Association Study of Liver Fat: The Multiethnic Cohort Adiposity Phenotype Study
  S. Lani Park, Yuqing Li, Xin Sheng, Victor Hom, Lucy Xia, Kechen Zhao, Loreall Pooler, V. Wendy Setiawan, Unhee Lim, Kristine R. Monroe, Lynne R. Wilkens, Bruce S. Kristal, Johanna W. Lampe, Meredith Hullar, John Shepherd, Lenora L. M. Loo, Thomas Ernst,
  Hepatology Communications.2020; 4(8): 1112.     CrossRef
• Non-alcoholic fatty liver disease in inflammatory bowel disease patients
  Katerina Karaivazoglou, Christos Konstantakis, Evanthia Tourkochristou, Stelios F. Assimakopoulos, Christos Triantos
  European Journal of Gastroenterology & Hepatology.2020; 32(8): 903.     CrossRef
• Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis
  Irma Garcia-Martinez, Rosa Alen, Patricia Rada, Angela M. Valverde
  Frontiers in Medicine.2020;[Epub]     CrossRef
• Triose Kinase Controls the Lipogenic Potential of Fructose and Dietary Tolerance
  Lei Liu, Tian Li, Yilie Liao, Yalong Wang, Yang Gao, Haikun Hu, Haipeng Huang, Fang Wu, Ye-Guang Chen, Shuhua Xu, Suneng Fu
  Cell Metabolism.2020; 32(4): 605.     CrossRef
• Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers
  Olfa Khalifa, Khaoula Errafii, Nayla S. Al-Akl, Abdelilah Arredouani
  Disease Markers.2020; 2020: 1.     CrossRef
• Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes
  Rohitash Jamwal, Benjamin J. Barlock
  Pharmaceuticals.2020; 13(9): 222.     CrossRef
• Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management
  Tony (Dazhong) Huang, Jason Behary, Amany Zekry
  Internal Medicine Journal.2020; 50(9): 1038.     CrossRef
• Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
  Silvia Sookoian, Carlos J. Pirola
  Clinical and Molecular Hepatology.2020; 26(4): 461.     CrossRef
• The association of genetic polymorphisms with nonalcoholic fatty liver disease in a longitudinal study
  Goh Eun Chung, Eunsoon Shin, Min-Sun Kwak, Jong In Yang, Jong-Eun Lee, Eun Kyung Choe, Jeong Yoon Yim
  BMC Gastroenterology.2020;[Epub]     CrossRef
• Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally
  Ma Ai Thanda Han, Qi Yu, Zaid Tafesh, Nikolaos Pyrsopoulos
  Journal of Clinical and Translational Hepatology.2020; 000(000): 1.     CrossRef
• Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease
  Cosimo Colletta, Alessandro Colletta, Giuseppe Placentino
  Journal of Diabetes & Metabolic Disorders.2020; 19(2): 883.     CrossRef
• Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
  Meegun Hong, Dae Hee Han, Jitaek Hong, Dong Joon Kim, Ki Tae Suk
  Probiotics and Antimicrobial Proteins.2019; 11(2): 335.     CrossRef
• Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach
  A. Feldman, S.K. Eder, T.K. Felder, B. Paulweber, S. Zandanell, L. Stechemesser, M. Schranz, G. Strebinger, U. Huber-Schönauer, D. Niederseer, W. Patsch, D. Weghuber, J. Tevini, C. Datz, E. Aigner
  Diabetes & Metabolism.2019; 45(2): 132.     CrossRef
• Molecular pathways of nonalcoholic fatty liver disease development and progression
  Fernando Bessone, María Valeria Razori, Marcelo G. Roma
  Cellular and Molecular Life Sciences.2019; 76(1): 99.     CrossRef
• Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
  David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
  Clinical and Molecular Hepatology.2019; 25(3): 283.     CrossRef
• Genetics Meets Therapy? Exome‐wide Association Study Reveals a Loss‐of‐Function Variant in 17‐Beta‐Hydroxysteroid Dehydrogenase 13 That Protects Patients From Liver Damage and Nonalcoholic Fatty Liver Disease Progression
  Silvia Sookoian, Marco Arrese, Carlos J. Pirola
  Hepatology.2019; 69(2): 907.     CrossRef
• Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
  Hsu-Wen Chao, Shi-Wei Chao, Heng Lin, Hui-Chen Ku, Ching-Feng Cheng
  International Journal of Molecular Sciences.2019; 20(2): 298.     CrossRef
• A Multifaceted Approach regarding the Association of the DsbA-L Gene with the Risk of Obesity-related Diseases Based on Clinical Pharmacogenetics
  Kentaro Oniki, Junji Saruwatari
  YAKUGAKU ZASSHI.2019; 139(1): 53.     CrossRef
• Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease
  Carlos J. Pirola, Martin Garaycoechea, Diego Flichman, Marco Arrese, Julio San Martino, Carla Gazzi, Gustavo O. Castaño, Silvia Sookoian
  Journal of Lipid Research.2019; 60(1): 176.     CrossRef
• Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease
  Ki Tae Suk, Dong Joon Kim
  Expert Review of Gastroenterology & Hepatology.2019; 13(3): 193.     CrossRef
• An integrative systems genetic analysis of mammalian lipid metabolism
  Benjamin L. Parker, Anna C. Calkin, Marcus M. Seldin, Michael F. Keating, Elizabeth J. Tarling, Pengyi Yang, Sarah C. Moody, Yingying Liu, Eser J. Zerenturk, Elise J. Needham, Matthew L. Miller, Bethan L. Clifford, Pauline Morand, Matthew J. Watt, Ruth C.
  Nature.2019; 567(7747): 187.     CrossRef
• Obesity genetics and cardiometabolic health: Potential for risk prediction
  Dharambir K. Sanghera, Cynthia Bejar, Sonali Sharma, Rajeev Gupta, Piers R. Blackett
  Diabetes, Obesity and Metabolism.2019; 21(5): 1088.     CrossRef
• Combined effects of ambient particulate matter exposure and a high-fat diet on oxidative stress and steatohepatitis in mice
  Shibin Ding, Chunyan Yuan, Bingjie Si, Mengruo Wang, Shuyan Da, Lanxin Bai, Weidong Wu, Qinghua Sun
  PLOS ONE.2019; 14(3): e0214680.     CrossRef
• Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease
  Mercedes del Río-Moreno, Emilia Alors-Pérez, Sandra González-Rubio, Gustavo Ferrín, Oscar Reyes, Manuel Rodríguez-Perálvarez, Marina E Sánchez-Frías, Rafael Sánchez-Sánchez, Sebastián Ventura, José López-Miranda, Rhonda D Kineman, Manuel de la Mata, Justo
  The Journal of Clinical Endocrinology & Metabolism.2019; 104(8): 3389.     CrossRef
• GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network
  Bahram Namjou, Todd Lingren, Yongbo Huang, Sreeja Parameswaran, Beth L. Cobb, Ian B. Stanaway, John J. Connolly, Frank D. Mentch, Barbara Benoit, Xinnan Niu, Wei-Qi Wei, Robert J. Carroll, Jennifer A. Pacheco, Isaac T. W. Harley, Senad Divanovic, David S.
  BMC Medicine.2019;[Epub]     CrossRef
• TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population
  Qun Liu, Shou-Sheng Liu, Zhen-Zhen Zhao, Ben-Tian Zhao, Shui-Xian Du, Wen-Wen Jin, Yong-Ning Xin
  Lipids in Health and Disease.2019;[Epub]     CrossRef
• Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient
  Shahinul Alam, Mohammad Jahid Hasan, Md. Abdullah Saeed Khan, Mahabubul Alam, Nazmul Hasan
  Journal of Translational Internal Medicine.2019; 7(3): 106.     CrossRef
• Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs
  Michele d’Angelo, Vanessa Castelli, Maria Grazia Tupone, Mariano Catanesi, Andrea Antonosante, Reyes Dominguez-Benot, Rodolfo Ippoliti, Anna Maria Cimini, Elisabetta Benedetti
  International Journal of Molecular Sciences.2019; 20(21): 5422.     CrossRef
• Network Modeling Approaches and Applications to Unravelling Non-Alcoholic Fatty Liver Disease
  Montgomery Blencowe, Tilan Karunanayake, Julian Wier, Neil Hsu, Xia Yang
  Genes.2019; 10(12): 966.     CrossRef
• Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations
  Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand
  Journal of Clinical and Translational Hepatology.2019; X(X): 1.     CrossRef
• Systematic review with meta‐analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease
  S. Sookoian, C. J. Pirola
  Alimentary Pharmacology & Therapeutics.2018; 47(1): 16.     CrossRef
• Sex differences between parental pregnancy characteristics and nonalcoholic fatty liver disease in adolescents
  Oyekoya T. Ayonrinde, Leon A. Adams, Trevor A. Mori, Lawrence J. Beilin, Nicholas de Klerk, Craig E. Pennell, Scott White, John K Olynyk
  Hepatology.2018; 67(1): 108.     CrossRef
• Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease
  Lindsey S Treviño, Tiffany A Katz
  Endocrinology.2018; 159(1): 20.     CrossRef
• Lean NAFLD: A not so benign condition?
  Lisa B. VanWagner, Matthew J. Armstrong
  Hepatology Communications.2018; 2(1): 5.     CrossRef
• Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
  Julia Wattacheril, Danny Issa, Arun Sanyal
  Annual Review of Pharmacology and Toxicology.2018; 58(1): 649.     CrossRef
• Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy
  Alessia Di Costanzo, Francesca Belardinilli, Diego Bailetti, Marialuisa Sponziello, Laura D’Erasmo, Licia Polimeni, Francesco Baratta, Daniele Pastori, Fabrizio Ceci, Anna Montali, Gabriella Girelli, Bruna De Masi, Antonio Angeloni, Giuseppe Giannini, Mar
  Scientific Reports.2018;[Epub]     CrossRef
• Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study
  Umberto Vespasiani-Gentilucci, Chiara Dell’Unto, Antonio De Vincentis, Andrea Baiocchini, Marco Delle Monache, Roberto Cecere, Adriano Maria Pellicelli, Valerio Giannelli, Simone Carotti, Giovanni Galati, Paolo Gallo, Francesco Valentini, Franca Del Nonno
  Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1.     CrossRef
• Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica
  Rocío Aller, Conrado Fernández-Rodríguez, Oreste lo Iacono, Rafael Bañares, Javier Abad, José Antonio Carrión, Carmelo García-Monzón, Joan Caballería, Marina Berenguer, Manuel Rodríguez-Perálvarez, José López Miranda, Eduardo Vilar-Gómez, Javier Crespo, M
  Gastroenterología y Hepatología.2018; 41(5): 328.     CrossRef
• NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?
  Subada Soti, Kathleen E. Corey, Jordan E. Lake, Kristine M. Erlandson
  Current HIV/AIDS Reports.2018; 15(3): 212.     CrossRef
• Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity
  Carlos J Pirola, Silvia Sookoian
  World Journal of Gastroenterology.2018; 24(15): 1601.     CrossRef
• The gut–liver axis and the intersection with the microbiome
  Anupriya Tripathi, Justine Debelius, David A. Brenner, Michael Karin, Rohit Loomba, Bernd Schnabl, Rob Knight
  Nature Reviews Gastroenterology & Hepatology.2018; 15(7): 397.     CrossRef
• Nonalcoholic Steatohepatitis
  Michael H. Schild, Cynthia D. Guy
  Surgical Pathology Clinics.2018; 11(2): 267.     CrossRef
• Dietary carbohydrates and fatty liver disease
  Sally Chiu, Kathleen Mulligan, Jean-Marc Schwarz
  Current Opinion in Clinical Nutrition & Metabolic Care.2018; 21(4): 277.     CrossRef
• Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
  Rocío Aller, Conrado Fernández-Rodríguez, Oreste lo Iacono, Rafael Bañares, Javier Abad, José Antonio Carrión, Carmelo García-Monzón, Joan Caballería, Marina Berenguer, Manuel Rodríguez-Perálvarez, José López Miranda, Eduardo Vilar-Gómez, Javier Crespo, M
  Gastroenterología y Hepatología (English Edition).2018; 41(5): 328.     CrossRef
• Integrated transcriptomics and metabolomics reveal signatures of lipid metabolism dysregulation in HepaRG liver cells exposed to PCB 126
  Robin Mesnage, Martina Biserni, Sucharitha Balu, Clément Frainay, Nathalie Poupin, Fabien Jourdan, Eva Wozniak, Theodoros Xenakis, Charles A. Mein, Michael N. Antoniou
  Archives of Toxicology.2018; 92(8): 2533.     CrossRef
• Mechanisms of NAFLD development and therapeutic strategies
  Scott L. Friedman, Brent A. Neuschwander-Tetri, Mary Rinella, Arun J. Sanyal
  Nature Medicine.2018; 24(7): 908.     CrossRef
• The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD)
  Amanda Hanson, Danielle Wilhelmsen, Johanna K. DiStefano
  Non-Coding RNA.2018; 4(3): 18.     CrossRef
• Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis
  Brett R Loman, Diego Hernández-Saavedra, Ruopeng An, R Scott Rector
  Nutrition Reviews.2018; 76(11): 822.     CrossRef
• Science, serendipity, and the single degree
  Helen H. Hobbs
  Journal of Clinical Investigation.2018; 128(10): 4218.     CrossRef
• Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics
  Min Seok Cho, Sang Yeol Kim, Ki Tae Suk, Byung-Yong Kim
  Journal of Microbiology.2018; 56(12): 855.     CrossRef
• Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables
  Umberto Vespasiani-Gentilucci, Paolo Gallo, Chiara Dell’Unto, Mara Volpentesta, Raffaele Antonelli-Incalzi, Antonio Picardi
  World Journal of Gastroenterology.2018; 24(43): 4835.     CrossRef
• Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse
  Silvia Sookoian, Carlos J. Pirola
  Annals of Hepatology.2018; 17(2): 182.     CrossRef
• Pediatric Non-Alcoholic Fatty Liver Disease
  Haley Bush, Pegah Golabi, Zobair M. Younossi
  Children.2017; 4(6): 48.     CrossRef
• A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease
  Paola Dongiovanni, Luca Valenti
  International Journal of Molecular Sciences.2017; 18(7): 1534.     CrossRef
• Hígado graso no alcohólico: una pandemia poco conocida
  Salvador Augustin, Isabel Graupera, Juan Caballeria
  Medicina Clínica.2017; 149(12): 542.     CrossRef
• Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals
  Giuseppe Della Pepa, Claudia Vetrani, Gianluca Lombardi, Lutgarda Bozzetto, Giovanni Annuzzi, Angela Rivellese
  Nutrients.2017; 9(10): 1065.     CrossRef
• What Is the Optimal Dietary Composition for NAFLD?
  Elena S. George, Audrey C. Tierney, Katrina L. Campbell, Graeme A. Macdonald, Ingrid J. Hickman
  Current Hepatology Reports.2017; 16(4): 346.     CrossRef
• Non-alcoholic fatty liver disease: A poorly known pandemic
  Salvador Augustin, Isabel Graupera, Juan Caballeria
  Medicina Clínica (English Edition).2017; 149(12): 542.     CrossRef

Citations

Citations to this article as recorded by  

• The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
  Milton Packer
  JACC.2025; 86(16): 1269.     CrossRef
• FABP4 Expression in Subcutaneous Adipose Tissue Is Independently Associated with Circulating Triglycerides in Obesity
  Óscar Osorio-Conles, Ainitze Ibarzabal, José María Balibrea, Josep Vidal, Emilio Ortega, Ana de Hollanda
  Journal of Clinical Medicine.2023; 12(3): 1013.     CrossRef
• Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease
  Juan Moreno-Vedia, Josefa Girona, Daiana Ibarretxe, Lluís Masana, Ricardo Rodríguez-Calvo
  Biomedicines.2022; 10(1): 197.     CrossRef
• Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?
  Vera Francisco, Maria Jesus Sanz, José T. Real, Patrice Marques, Maurizio Capuozzo, Djedjiga Ait Eldjoudi, Oreste Gualillo
  Biology.2022; 11(8): 1237.     CrossRef
• Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis
  Abdulrahman Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Dan L. Dumitrascu
  Journal of Clinical Medicine.2021; 10(14): 3029.     CrossRef
• Serum adipocyte fatty acid‐binding protein levels are associated with peripheral arterial disease in women, but not men, with type 2 diabetes mellitus
  Min Ding, Jian‐Ying Shi, Yun‐Zhi XING, Bei Sun, Qian‐Hua Fang, Jing‐Yun Zhang, Qiu‐Mei Zhang, Li‐Ming Chen, De‐min Yu, Chun‐Jun Li
  Journal of Diabetes.2018; 10(6): 478.     CrossRef
• Adipokines in nonalcoholic fatty liver disease
  Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
  Metabolism.2016; 65(8): 1062.     CrossRef
• Association of recently described adipokines with liver histology in biopsy‐proven non‐alcoholic fatty liver disease: a systematic review
  M. Bekaert, X. Verhelst, A. Geerts, B. Lapauw, P. Calders
  Obesity Reviews.2016; 17(1): 68.     CrossRef
• Evaluation of Circulating Adipokines and Abdominal Obesity as Predictors of Significant Myocardial Ischemia Using Gated Single-Photon Emission Computed Tomography
  Chi-Sheng Hung, Yen-Wen Wu, Jei-Yie Huang, Pei-Ying Hsu, Ming-Fong Chen, Xin-Liang Ma
  PLoS ONE.2014; 9(5): e97710.     CrossRef
• Serum visfatin in nonalcoholic fatty liver disease
  Stergios A. Polyzos, Jannis Kountouras, lordanis Romiopoulos, Vaia Polymerou
  Annals of Hepatology.2014; 13(1): 150.     CrossRef
• Systems biology of adipose tissue metabolism: regulation of growth, signaling and inflammation
  Sara Manteiga, Kyungoh Choi, Arul Jayaraman, Kyongbum Lee
  WIREs Systems Biology and Medicine.2013; 5(4): 425.     CrossRef
• Metabolically Protective Cytokines Adiponectin and Fibroblast Growth Factor-21 Are Increased by Acute Overfeeding in Healthy Humans
  Leonie K. Heilbronn, Lesley V. Campbell, Aimin Xu, Dorit Samocha-Bonet, Jose Galgani
  PLoS ONE.2013; 8(10): e78864.     CrossRef

Citations

Citations to this article as recorded by  

• Elevated red cell distribution width is associated with advanced fibrosis in NAFLD
  Hwa Mok Kim, Bum Soo Kim, Yong Kyun Cho, Byung Ik Kim, Chong Il Sohn, Woo Kyu Jeon, Hong Joo Kim, Dong Il Park, Jung Ho Park, Kwan Joong Joo, Chang Joon Kim, Yong Sung Kim, Woon Je Heo, Won Seok Choi
  Clinical and Molecular Hepatology.2013; 19(3): 258.     CrossRef
• Validity and reliability of the nonalcoholic fatty liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors
  Kyung-Hun Lee, Sang Hoon Park, Yu Jin Kim, Kyung Rim Huh, Kwang Seon Min, Sun-Young Jun, Kyoung Oh Kim, Cheol Hee Park, Taeho Hahn, Kyo-Sang Yoo, Jong Hyeok Kim, Myung-Seok Lee, Choong Kee Park
  The Korean Journal of Hepatology.2010; 16(1): 29.     CrossRef
• 
  Ko NOMURA
  Environmental Education.2010; 20(1): 6.     CrossRef
• Pathology of nonalcoholic steatohepatitis
  Yoon-Mi Jeen, So-Young Jin
  The Korean Journal of Hepatology.2009; 15(2): 122.     CrossRef
• The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology
  Stephen Caldwell, Sang H. Park
  Journal of Gastroenterology.2009; 44(S19): 96.     CrossRef